Brokerages expect Applied DNA Sciences, Inc. (NASDAQ:APDN – Get Rating) to report ($0.30) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Applied DNA Sciences’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.30). Applied DNA Sciences posted earnings of ($0.33) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 9.1%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Applied DNA Sciences will report full-year earnings of ($1.32) per share for the current financial year, with EPS estimates ranging from ($1.33) to ($1.30). For the next year, analysts expect that the business will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.94) to ($0.55). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Applied DNA Sciences.
Applied DNA Sciences (NASDAQ:APDN – Get Rating) last issued its quarterly earnings data on Thursday, February 10th. The technology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.44). The business had revenue of $4.17 million for the quarter, compared to the consensus estimate of $4.28 million. Applied DNA Sciences had a negative net margin of 123.04% and a negative return on equity of 105.86%. During the same period in the previous year, the business posted ($0.62) EPS.
Shares of APDN opened at $1.60 on Friday. The firm’s 50 day moving average price is $2.11 and its 200 day moving average price is $3.70. Applied DNA Sciences has a twelve month low of $1.57 and a twelve month high of $8.10.
Large investors have recently added to or reduced their stakes in the company. Delta Investment Management LLC raised its position in shares of Applied DNA Sciences by 50.0% in the third quarter. Delta Investment Management LLC now owns 15,002 shares of the technology company’s stock valued at $81,000 after purchasing an additional 5,002 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Applied DNA Sciences in the second quarter worth $85,000. Dimensional Fund Advisors LP grew its stake in shares of Applied DNA Sciences by 31.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,334 shares of the technology company’s stock worth $104,000 after acquiring an additional 4,616 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Applied DNA Sciences by 33.0% in the third quarter. Geode Capital Management LLC now owns 53,373 shares of the technology company’s stock worth $287,000 after acquiring an additional 13,257 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Applied DNA Sciences by 27.3% in the third quarter. BlackRock Inc. now owns 76,869 shares of the technology company’s stock worth $415,000 after acquiring an additional 16,493 shares during the last quarter. 8.24% of the stock is currently owned by institutional investors.
Applied DNA Sciences Company Profile (Get Rating)
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims.
- Get a free copy of the StockNews.com research report on Applied DNA Sciences (APDN)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.